CURE (Connecticut United for Research Excellence) Responds to New FDA Drug Labeling Rule
Posted on: Wednesday, 18 January 2006, 21:00 CST
NEW HAVEN, Conn., Jan. 18 /PRNewswire/ -- Paul R. Pescatello, president and chief executive officer of CURE (Connecticut United for Research Excellence), issued the following statement today in response to the new rule on drug labeling (package inserts) issued today by the U.S. Food and Drug Administration (FDA).
"For years patients have been faced with drug labeling that is overly complex and provides little understandable information about how their medicine should be taken. Even doctors are confused by the labeling, affecting their ability to act in the patients best interest.
"Today the FDA took a much-needed step to solve this problem by issuing new rules for drug labeling. Among other improvements, the new labeling will include special patient counseling and prescribing highlights. These sections will give patients understandable information that will help them become more knowledgeable about the medicine they are taking, while assisting physicians and reducing medical error.
"An important change is that the new labeling will no longer include the dense legalese describing obscure and rare side effects that is irrelevant to the needs of most patients. Inclusion of this mind-numbing material actually compromises understanding, but many manufactures have felt obligated to include it in order to ward off potential lawsuits.
"To discourage that practice, the FDA has restated, in the preamble to today's rule, a principle that it has long asserted: that the information included on an FDA-approved label pre-empts product liability lawsuits based on conflicting state laws. This is a fair and reasonable position that will help bring much needed clarity to drug labeling."
CURE (http://www.curenet.org/) is a statewide coalition of over 100 educational and research institutions, biotechnology and pharmaceutical companies and other supporting businesses. It is dedicated to promoting the growth and increasing public understanding of biomedical research and science in Connecticut.
Connecticut United for Research Excellence, Inc.
CONTACT: Bill Kelly for CURE, +1-203-375-2696, bill@harveymalis.com
Web site: http://www.curenet.org/
Source: PRNewswire
Related Articles
- Some Doctors in the Dark About Off-Label Drugs
- IROs Help Decide Medically on Approved Uses of Off-Label Drugs for Cancer
- Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use
- TyRx Pharma, Inc. Announces Food and Drug Administration (FDA) 510(K) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacem
- Sumner M. Redstone Commits $105 Million to Fund Cancer and Burn Recovery Research and Patient Care
- TYZEKA(TM) (Telbivudine) Approved By U.S. Food and Drug Administration (FDA) As a New Treatment for Patients With Chronic Hepatitis B
- Geron Announces FDA Clearance to Start Clinical Trials of Its Telomerase Inhibitor Drug GRN163L in Patients With Chronic Lymphocytic Leukemia
- U.S. Food and Drug Administration (FDA) Approves BARACLUDE(TM) (Entecavir) for Treatment of Chronic Hepatitis B
 |
 |
User Comments (0)
RSS Feeds